KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessShares IssuedShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) R&D In Process (2016 - 2025)

Historic R&D In Process for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $2.7 billion.

  • AbbVie's R&D In Process rose 316829.27% to $2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year increase of 26641.64%. This contributed to the annual value of $2.8 billion for FY2024, which is 25989.72% up from last year.
  • According to the latest figures from Q3 2025, AbbVie's R&D In Process is $2.7 billion, which was up 316829.27% from $823.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's R&D In Process registered a high of $2.7 billion during Q3 2025, and its lowest value of $40.0 million during Q3 2022.
  • Its 5-year average for R&D In Process is $481.6 million, with a median of $248.0 million in 2025.
  • As far as peak fluctuations go, AbbVie's R&D In Process tumbled by 9004.98% in 2022, and later surged by 316829.27% in 2025.
  • Over the past 5 years, AbbVie's R&D In Process (Quarter) stood at $405.0 million in 2021, then crashed by 40.0% to $243.0 million in 2022, then increased by 16.05% to $282.0 million in 2023, then skyrocketed by 473.4% to $1.6 billion in 2024, then surged by 65.74% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q3 2025, $823.0 million for Q2 2025, and $248.0 million during Q1 2025.